US20100179319A1 - Process for production of optically active mirtazapine - Google Patents
Process for production of optically active mirtazapine Download PDFInfo
- Publication number
- US20100179319A1 US20100179319A1 US12/667,969 US66796908A US2010179319A1 US 20100179319 A1 US20100179319 A1 US 20100179319A1 US 66796908 A US66796908 A US 66796908A US 2010179319 A1 US2010179319 A1 US 2010179319A1
- Authority
- US
- United States
- Prior art keywords
- mirtazapine
- optically active
- tartaric acid
- water
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KRLHGDFNSAUUFU-CQYLEEIWSA-N CN1CCN2C3=NC=CC=C3CC3=C(C=CC=C3)C2C1.[H][C@@]12CN(C)CCN1C1=NC=CC=C1CC1=C2C=CC=C1.[H][C@]12CN(C)CCN1C1=NC=CC=C1CC1=C2C=CC=C1 Chemical compound CN1CCN2C3=NC=CC=C3CC3=C(C=CC=C3)C2C1.[H][C@@]12CN(C)CCN1C1=NC=CC=C1CC1=C2C=CC=C1.[H][C@]12CN(C)CCN1C1=NC=CC=C1CC1=C2C=CC=C1 KRLHGDFNSAUUFU-CQYLEEIWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Definitions
- the present invention relates to a process for production of optically active mirtazapine.
- Patent document 1 Japanese Unexamined Patent Publication SHO No. 51-122093
- the present invention provides a process for producing optically active mirtazapine wherein an RS mixture of mirtazapine is optically resolved with optically active tartaric acid in the presence of a solvent.
- FIG. 1 is a 1H-NMR spectrum chart for the L-tartaric acid salt of S-mirtazapine (Example 1).
- FIG. 2 is a 1H-NMR spectrum chart for S-mirtazapine (Reference Example 1).
- FIG. 3 shows the XRD data for S-mirtazapine (Reference Example 1).
- FIG. 4 is a 1H-NMR spectrum chart for S-mirtazapine (Reference Example 2).
- FIG. 5 shows the XRD data for S-mirtazapine (Reference Example 2).
- FIG. 6 is a 1H-NMR spectrum chart for the D-tartaric acid salt of R-mirtazapine (Example 2).
- Mirtazapine is a compound represented by the following formula, and it exists as two isomers, the R-form and S-form.
- an RS mixture of mirtazapine is a mixture consisting of the R-form and S-form of mirtazapine in any proportion, and it may be a completely racemic mixture or it may contain either isomer in excess.
- optically active tartaric acid used may be a commercially available product in most cases. Preferred from the viewpoint of cost is L-tartaric acid.
- optically active tartaric acid used will usually be in the range of 0.5 to 1.5-fold moles and preferably 0.8 to 1.2-fold moles with respect to the RS mixture of mirtazapine.
- solvents examples include water-soluble organic solvents, water, and mixtures thereof.
- a mixed solvent consisting of a water-soluble organic solvent and water is preferred.
- the mixed solvent may be obtained by premixing the water-soluble organic solvent and water, or these may be mixed in the system during the optical resolution procedure.
- the mixing proportion of the water-soluble organic solvent and water is not particularly restricted, but it will usually be in the range of 1 to 100 times by weight and preferably 3 to 50 times by weight of the water-soluble organic solvent with respect to the water.
- the water-soluble organic solvent is not particularly restricted so long as it is an organic solvent that can be homogeneously mixed with water in any proportion, and examples thereof include ether solvents such as tetrahydrofuran, 1,2-dimethoxymethane, 1,2-dimethoxyethane, diglyme, dioxane and 1,3-dioxolane; alcohol solvents such as methanol, ethanol, 1-propanol, 2-propanol, 2-methoxyethanol and 2-ethoxyethanol; ketone solvents such as acetone; sulfur-containing solvents such as dimethyl sulfoxide and sulfolane; nitrogen-containing solvents such as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N,N-dimethylpropionamide, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyr
- the amount of solvent used will usually be in the range of 1 to 50 times by weight and preferably 5 to 20 times by weight with respect to the RS mixture of mirtazapine.
- the optical resolution of the invention is carried out by making the RS mixture of mirtazapine contact with the optically active tartaric acid in the presence of the solvent.
- the order of combining the solvent, the RS mixture of mirtazapine and the optically active tartaric acid is not particularly restricted, and after being adjusted to a prescribed mixing temperature, an optically active mirtazapine salt will be preferentially deposited in most cases by cooling the mixture if necessary.
- Examples of specific modes include a mode in which the solvent, the RS mixture of mirtazapine and the optically active tartaric acid are combined all at once and the obtained mixture is adjusted to a prescribed mixing temperature to obtain a homogeneous solution, after which the solution is cooled for preferential deposition of an optically active mirtazapine salt; and a mode in which the RS mixture of mirtazapine is combined with a water-soluble organic solvent and the mixture is adjusted to a prescribed mixing temperature, after which optically active tartaric acid is added to and mixed with the mixture to form a homogeneous solution, water is added to and mixed therewith, and if necessary the mixture is cooled to preferentially deposit an optically active mirtazapine salt.
- the optically active mirtazapine salt may be used as seed crystals if necessary.
- the preferred mode is a mode in which the RS mixture of mirtazapine is combined with a water-soluble organic solvent and the mixture is adjusted to a prescribed mixing temperature, after which optically active tartaric acid is added to and mixed with the mixture to form a homogeneous solution, water is added thereto and mixed therewith to preferentially deposit an optically active mirtazapine salt, by cooling the mixture if necessary. Water may be further added during cooling or after cooling.
- the mixture may be cooled with the crystals or cooled after separating out the crystals, or it may be cooled after heating to dissolve the crystals, or the crystals may be separated out without cooling and subjected to the following post-treatment.
- the mixing temperature is in the range of usually 35 to 100° C. and preferably 35 to 65° C.
- the temperature upon completion of cooling is in the range of usually ⁇ 10 to 30° C. and preferably 5 to 30° C.
- the mixture obtained by the optical resolution will normally contain the optically active mirtazapine salt crystals, and the optically active mirtazapine salt can be obtained by separating the crystals from the mixture. The separation may be accomplished by procedures such as filtration or decantation. If necessary, the solvent may be used for washing treatment of the optically active mirtazapine salt that has been obtained.
- the optically active mirtazapine salt may also be purified by ordinary purifying treatment such as recrystallization or column chromatography.
- the liquid phase obtained by the separation may contain an abundant amount of optically active mirtazapine having the opposite configuration to that of the optically active mirtazapine salt that has been obtained, in which case the optically active mirtazapine may be isolated by ordinary post-treatment of the liquid phase, such as washing, concentration, distillation and crystallization.
- the optically active mirtazapine salt obtained by the separation consists of optically active mirtazapine and optically active tartaric acid, and if L-tartaric acid is used as the optically active tartaric acid the optically active mirtazapine in the salt will normally be rich in the S-form, while if D-tartaric acid is used as the optically active tartaric acid the optically active mirtazapine in the salt will normally be rich in the R-form.
- the optically active mirtazapine salt may also be a hydrate. Making the optically active mirtazapine salt contact with a base will yield the corresponding optically active mirtazapine.
- Examples of such bases include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogencarbonates such as sodium hydrogencarbonate and potassium hydrogencarbonate; alkali metal alcoholates such as sodium methylate and sodium ethylate; and tertiary amines such as triethylamine, diisopropylethylamine and tributylamine.
- alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide
- alkali metal carbonates such as sodium carbonate and potassium carbonate
- alkali metal hydrogencarbonates such as sodium hydrogencarbonate and potassium hydrogencarbonate
- alkali metal alcoholates such as sodium methylate and sodium ethylate
- tertiary amines such as triethylamine, diisopropylethylamine and tributylamine.
- Contact between the optically active mirtazapine salt and base can be accomplished in the presence of a solvent in most cases.
- solvents include water; alcohol solvents such as methanol, ethanol and 2-propanol; and ether solvents such as tetrahydrofuran.
- the amount of base used will usually be in the range of 0.5 to 2-fold moles of the optically active tartaric acid in the optically active mirtazapine salt.
- the contact temperature for the optically active mirtazapine salt and base will usually be in the range of 0 to 50° C. There are no particular restrictions on the order of mixing the optically active mirtazapine and base.
- the optically active mirtazapine salt and base may be contacted by ordinary post-treatment of the obtained mixture, such as liquid separation, concentration, distillation and crystallization. Specifically, there is a mode of liquid separation after combining with water and/or an organic solvent that is immiscible with water if necessary, and concentration of the obtained organic layer.
- the optically active mirtazapine may be further purified by ordinary purifying treatment such as recrystallization or column chromatography.
- the optical purity of mirtazapine was determined by the high-performance liquid chromatography area percentage.
- the analysis conditions were as follows.
- Retention time 6.3 minutes (R-mirtazapine), 7.4 minutes (S-mirtazapine)
- the crystals were separated from the obtained mixture by filtration, washed with 25 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 12.5 g of crude crystals of the L-tartaric acid salt of S-mirtazapine as a white powder. After mixing 12.5 g of the crude crystals with 60 mL of methanol, the mixture was heated to 45° C. and mixed, causing complete dissolution of the crystals. After adding 1.5 mL of water thereto and mixing, deposition of crystals was observed. The obtained mixture was heated to 64° C. for dissolution of the crystals, and then cooled to 40° C. over a period of about 1 hour, upon which crystals were deposited.
- FIG. 1 shows a 1H-NMR spectrum chart for the L-tartaric acid salt of S-mirtazapine.
- the 1H-NMR spectrum chart is shown in FIG. 2
- the XRD data are shown in FIG. 3 .
- the 1H-NMR spectrum chart is shown in FIG. 4
- the XRD data are shown in FIG. 5 .
- the crystals were separated from the obtained mixture by filtration, washed with 25 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 12.8 g of crude crystals of the D-tartaric acid salt of R-mirtazapine as a white powder.
- the optical purity of the R-mirtazapine in the obtained crude crystals was 97.4% ee.
- FIG. 6 shows the 1H-NMR spectrum chart for the D-tartaric acid salt of R-mirtazapine.
- Optically active mirtazapine is useful as a therapeutic agent for sleep disorders, for example (see International Patent Publication No. 2006/51111), and according to the invention the compound can be efficiently and inexpensively produced.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a process for efficiently producing optically active mirtazapine. Specifically, a process for production of optically active mirtazapine wherein an RS mixture of mirtazapine is optically resolved with optically active tartaric acid in the presence of a solvent. More specifically, a process for production of optically active mirtazapine, characterized by making an RS mixture of mirtazapine contact with optically active tartaric acid in the presence of a solvent, and preferentially crystallizing the optically active mirtazapine salt. The solvent is preferably a mixed solvent consisting of a water-soluble organic solvent and water, and more preferably a mixed solvent consisting of a C1-3 alcohol and water.
Description
- The present invention relates to a process for production of optically active mirtazapine.
- Known processes for production of optically active mirtazapine include processes in which optically active O,O-dibenzoyltartaric acid is used for optical resolution of RS mixtures of mirtazapine (see Patent document 1). However, such processes give low yields despite the use of relatively expensive resolving agents, and they are therefore unsatisfactory from an industrial standpoint.
- [Patent document 1] Japanese Unexamined Patent Publication SHO No. 51-122093
- With this in mind, the present inventors diligently researched methods for efficiently producing optically active mirtazapine by optical resolution of RS mixtures of mirtazapine, and as a result they have completed this invention upon finding that optically active mirtazapine can be obtained efficiently by using inexpensive optically active tartaric acid as the resolving agent.
- Specifically, the present invention provides a process for producing optically active mirtazapine wherein an RS mixture of mirtazapine is optically resolved with optically active tartaric acid in the presence of a solvent.
- According to the invention, it is possible to accomplish efficient optical resolution of RS mixtures of mirtazapine. Furthermore, the process is industrially advantageous from a cost standpoint since the resolving agent is inexpensive.
-
FIG. 1 is a 1H-NMR spectrum chart for the L-tartaric acid salt of S-mirtazapine (Example 1). -
FIG. 2 is a 1H-NMR spectrum chart for S-mirtazapine (Reference Example 1). -
FIG. 3 shows the XRD data for S-mirtazapine (Reference Example 1). -
FIG. 4 is a 1H-NMR spectrum chart for S-mirtazapine (Reference Example 2). -
FIG. 5 shows the XRD data for S-mirtazapine (Reference Example 2). -
FIG. 6 is a 1H-NMR spectrum chart for the D-tartaric acid salt of R-mirtazapine (Example 2). - The invention will now be explained in detail.
- Mirtazapine is a compound represented by the following formula, and it exists as two isomers, the R-form and S-form.
- For the purpose of the invention, an RS mixture of mirtazapine is a mixture consisting of the R-form and S-form of mirtazapine in any proportion, and it may be a completely racemic mixture or it may contain either isomer in excess.
- The optically active tartaric acid used may be a commercially available product in most cases. Preferred from the viewpoint of cost is L-tartaric acid.
- The amount of optically active tartaric acid used will usually be in the range of 0.5 to 1.5-fold moles and preferably 0.8 to 1.2-fold moles with respect to the RS mixture of mirtazapine.
- Examples of solvents include water-soluble organic solvents, water, and mixtures thereof. A mixed solvent consisting of a water-soluble organic solvent and water is preferred. The mixed solvent may be obtained by premixing the water-soluble organic solvent and water, or these may be mixed in the system during the optical resolution procedure. The mixing proportion of the water-soluble organic solvent and water is not particularly restricted, but it will usually be in the range of 1 to 100 times by weight and preferably 3 to 50 times by weight of the water-soluble organic solvent with respect to the water.
- The water-soluble organic solvent is not particularly restricted so long as it is an organic solvent that can be homogeneously mixed with water in any proportion, and examples thereof include ether solvents such as tetrahydrofuran, 1,2-dimethoxymethane, 1,2-dimethoxyethane, diglyme, dioxane and 1,3-dioxolane; alcohol solvents such as methanol, ethanol, 1-propanol, 2-propanol, 2-methoxyethanol and 2-ethoxyethanol; ketone solvents such as acetone; sulfur-containing solvents such as dimethyl sulfoxide and sulfolane; nitrogen-containing solvents such as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, N,N-dimethylpropionamide, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyridinone; lactone solvents such as γ-butyrolactone; and carbonic acid ester solvents such as dimethyl carbonate. Alcohol solvents are preferred, with methanol being more preferred.
- The amount of solvent used will usually be in the range of 1 to 50 times by weight and preferably 5 to 20 times by weight with respect to the RS mixture of mirtazapine.
- The optical resolution of the invention is carried out by making the RS mixture of mirtazapine contact with the optically active tartaric acid in the presence of the solvent. The order of combining the solvent, the RS mixture of mirtazapine and the optically active tartaric acid is not particularly restricted, and after being adjusted to a prescribed mixing temperature, an optically active mirtazapine salt will be preferentially deposited in most cases by cooling the mixture if necessary. Examples of specific modes include a mode in which the solvent, the RS mixture of mirtazapine and the optically active tartaric acid are combined all at once and the obtained mixture is adjusted to a prescribed mixing temperature to obtain a homogeneous solution, after which the solution is cooled for preferential deposition of an optically active mirtazapine salt; and a mode in which the RS mixture of mirtazapine is combined with a water-soluble organic solvent and the mixture is adjusted to a prescribed mixing temperature, after which optically active tartaric acid is added to and mixed with the mixture to form a homogeneous solution, water is added to and mixed therewith, and if necessary the mixture is cooled to preferentially deposit an optically active mirtazapine salt. In this method of optical resolution, the optically active mirtazapine salt may be used as seed crystals if necessary. The preferred mode is a mode in which the RS mixture of mirtazapine is combined with a water-soluble organic solvent and the mixture is adjusted to a prescribed mixing temperature, after which optically active tartaric acid is added to and mixed with the mixture to form a homogeneous solution, water is added thereto and mixed therewith to preferentially deposit an optically active mirtazapine salt, by cooling the mixture if necessary. Water may be further added during cooling or after cooling. When the optically active mirtazapine salt is deposited as crystals during the water-addition stage, the mixture may be cooled with the crystals or cooled after separating out the crystals, or it may be cooled after heating to dissolve the crystals, or the crystals may be separated out without cooling and subjected to the following post-treatment.
- The mixing temperature is in the range of usually 35 to 100° C. and preferably 35 to 65° C. The temperature upon completion of cooling is in the range of usually −10 to 30° C. and preferably 5 to 30° C.
- The mixture obtained by the optical resolution will normally contain the optically active mirtazapine salt crystals, and the optically active mirtazapine salt can be obtained by separating the crystals from the mixture. The separation may be accomplished by procedures such as filtration or decantation. If necessary, the solvent may be used for washing treatment of the optically active mirtazapine salt that has been obtained. The optically active mirtazapine salt may also be purified by ordinary purifying treatment such as recrystallization or column chromatography.
- The liquid phase obtained by the separation may contain an abundant amount of optically active mirtazapine having the opposite configuration to that of the optically active mirtazapine salt that has been obtained, in which case the optically active mirtazapine may be isolated by ordinary post-treatment of the liquid phase, such as washing, concentration, distillation and crystallization.
- The optically active mirtazapine salt obtained by the separation consists of optically active mirtazapine and optically active tartaric acid, and if L-tartaric acid is used as the optically active tartaric acid the optically active mirtazapine in the salt will normally be rich in the S-form, while if D-tartaric acid is used as the optically active tartaric acid the optically active mirtazapine in the salt will normally be rich in the R-form. The optically active mirtazapine salt may also be a hydrate. Making the optically active mirtazapine salt contact with a base will yield the corresponding optically active mirtazapine.
- Examples of such bases include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogencarbonates such as sodium hydrogencarbonate and potassium hydrogencarbonate; alkali metal alcoholates such as sodium methylate and sodium ethylate; and tertiary amines such as triethylamine, diisopropylethylamine and tributylamine.
- Contact between the optically active mirtazapine salt and base can be accomplished in the presence of a solvent in most cases. Examples of such solvents include water; alcohol solvents such as methanol, ethanol and 2-propanol; and ether solvents such as tetrahydrofuran. The amount of base used will usually be in the range of 0.5 to 2-fold moles of the optically active tartaric acid in the optically active mirtazapine salt.
- The contact temperature for the optically active mirtazapine salt and base will usually be in the range of 0 to 50° C. There are no particular restrictions on the order of mixing the optically active mirtazapine and base.
- After the optically active mirtazapine salt and base have been contacted, the optically active mirtazapine may be isolated by ordinary post-treatment of the obtained mixture, such as liquid separation, concentration, distillation and crystallization. Specifically, there is a mode of liquid separation after combining with water and/or an organic solvent that is immiscible with water if necessary, and concentration of the obtained organic layer. The optically active mirtazapine may be further purified by ordinary purifying treatment such as recrystallization or column chromatography.
- The present invention will now be further explained by examples, with the understanding that the invention is not limited by the examples.
- For each of the examples, the optical purity of mirtazapine was determined by the high-performance liquid chromatography area percentage. The analysis conditions were as follows.
- Column: CHIRALCEL OD-H 4.6 mm×250 mm, 40° C.
- Mobile phase: hexane/2-propanol (9/1)
- Flow rate: 1 ml/min
- Detector: UV (290 nm)
- Retention time: 6.3 minutes (R-mirtazapine), 7.4 minutes (S-mirtazapine)
- After combining 15.0 g (56.5 mmol, racemic mixture) of mirtazapine and 180 mL of methanol, the obtained mixture was heated to 50° C. To this there was added L-tartaric acid 8.65 g (57.6 mmol), and the mixture was agitated to obtain a homogeneous solution. Upon adding 18 mL of water dropwise thereto at the same temperature over a period of about 5 minutes, crystals were deposited. The obtained mixture was heated to 60° C. to dissolve most of the crystals, and then cooled to 25° C. over a period of about 22 hours. The crystals were separated from the obtained mixture by filtration, washed with 25 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 12.5 g of crude crystals of the L-tartaric acid salt of S-mirtazapine as a white powder. After mixing 12.5 g of the crude crystals with 60 mL of methanol, the mixture was heated to 45° C. and mixed, causing complete dissolution of the crystals. After adding 1.5 mL of water thereto and mixing, deposition of crystals was observed. The obtained mixture was heated to 64° C. for dissolution of the crystals, and then cooled to 40° C. over a period of about 1 hour, upon which crystals were deposited. After adding 4.5 mL of water over a period of 1 hour, the mixture was cooled to 25° C. over a period of about 15 hours. The crystals were separated from the obtained mixture by filtration, washed with 15 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 11.9 g of crude crystals of the L-tartaric acid salt of S-mirtazapine as a white powder. The optical purity of the S-mirtazapine in the obtained crystals was 100% ee. The water content of the crystals was 9.4 wt % as measured by the Karl Fischer method.
-
FIG. 1 shows a 1H-NMR spectrum chart for the L-tartaric acid salt of S-mirtazapine. - δ(ppm in DMSO-d6): 2.34 (1H, m), 2.37 (3H, s), 2.51 (1H, t-like, J=ca. 11 Hz), 2.86 (1H, dt, J=11.2 Hz), 2.96 (1H, dd, J=11.2 Hz), 3.42 (1H, d, J=13 Hz), 3.47 (1H, m), 3.69 (1H, m), 4.35 (1H, dd, J=10.4 Hz), 4.52 (1H, d, J=13 Hz), 6.73 (1H, dd, J=7.5 Hz), 7.09-7.17 (4H, m), 7.31 (1H, dd, J=7.2 Hz), 8.15 (1H, dd, J=5.2 Hz)
- A 10.6 g portion of the previously obtained L-tartaric acid salt of S-mirtazapine was combined with a solution of 2.6 g of sodium hydroxide dissolved in 20 mL of water, and extraction was performed with tert-butyl methyl ether (20 mL×2). Magnesium sulfate was used for dehydrating of the obtained organic layer, and the dehydrated organic layer was concentrated to obtain 6.10 g of S-mirtazapine as white crystals. The yield was 91% (based on mirtazapine (racemic mixture)).
- After combining 6.1 g of the S-mirtazapine obtained in Example 1 with 15 mL of heptane and dissolving the S-mirtazapine crystals at 50° C., the mixture was slowly cooled to 0 to 5° C., resulting in crystal deposition. The deposited crystals were obtained by filtration and then washed with 2 mL of heptane and dried to obtain 5.6 g of S-mirtazapine as white crystals. The crystal yield was 92%.
- Specific rotation [α]D23: 535° (c 0.1 methanol)
- Melting point (3 measurements): 86.0° C., 85.8° C., 85.9° C.
- The 1H-NMR spectrum chart is shown in
FIG. 2 , and the XRD data are shown inFIG. 3 . - After dissolving 4.2 g of the S-mirtazapine obtained in Reference Example 1 in 4 mL of acetone, 10 mL of water was slowly added dropwise at 40° C., resulting in deposition of crystals. The obtained mixture was stirred at 40° C. for 1 hour and then slowly cooled to 25° C. The deposited crystals were obtained by filtration and then washed with 2 mL of water and dried under reduced pressure at 25° C. to obtain 4.0 g of S-mirtazapine as white crystals. The crystal yield was 95%.
- Melting point (3 measurements): 84.7° C., 85.2° C., 84.2° C.
- The 1H-NMR spectrum chart is shown in
FIG. 4 , and the XRD data are shown inFIG. 5 . - After combining 15.0 g (56.5 mmol, racemic mixture) of mirtazapine, 8.65 g (57.6 mmol) of D-tartaric acid and 180 mL of methanol, the obtained mixture was heated to 50° C. and stirred to obtain a homogeneous solution. Upon adding 18 mL of water dropwise thereto at the same temperature over a period of about 105 minutes, crystals were deposited. The obtained mixture was cooled to 25° C. over a period of about 15 hours. The crystals were separated from the obtained mixture by filtration, washed with 25 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 12.8 g of crude crystals of the D-tartaric acid salt of R-mirtazapine as a white powder. The optical purity of the R-mirtazapine in the obtained crude crystals was 97.4% ee.
- After mixing 12.8 g of the crude crystals with 60 mL of methanol, the mixture was heated to 50° C. and mixed, causing complete dissolution of the crystals. Upon adding 6 mL of water thereto and mixing, crystals were deposited. The obtained mixture was cooled to 25° C. over a period of about 21 hours. The crystals were separated from the obtained mixture by filtration, washed with 5 mL of methanol-water (10:1) and then dried under reduced pressure to obtain 10.7 g of crude crystals of the D-tartaric acid salt of R-mirtazapine as a white powder. The optical purity of the R-mirtazapine in the obtained crystals was 100% ee. The water content of the crystals was 9.2 wt % as measured by the Karl Fischer method.
-
FIG. 6 shows the 1H-NMR spectrum chart for the D-tartaric acid salt of R-mirtazapine. - Optically active mirtazapine is useful as a therapeutic agent for sleep disorders, for example (see International Patent Publication No. 2006/51111), and according to the invention the compound can be efficiently and inexpensively produced.
Claims (10)
1. A process for production of optically active mirtazapine wherein an RS mixture of mirtazapine is optically resolved with optically active tartaric acid in the presence of a solvent.
2. A process for production of optically active mirtazapine, characterized by making an RS mixture of mirtazapine contact with optically active tartaric acid in the presence of a solvent, and preferentially crystallizing the optically active mirtazapine salt.
3. The process according to claim 2 , wherein the obtained optically active mirtazapine salt is further made to contact with a base.
4. The process according to claim 2 , wherein the solvent is a mixed solvent consisting of a water-soluble organic solvent and water.
5. The process according to claim 4 , wherein the water-soluble organic solvent is a C1-3 alcohol solvent.
6. The process according to claim 2 , wherein the optically active tartaric acid is L-tartaric acid and the obtained optically active mirtazapine is S-mirtazapine.
7. A salt consisting of optically active tartaric acid and optically active mirtazapine.
8. A salt consisting of L-tartaric acid and S-mirtazapine.
9. A salt consisting of D-tartaric acid and R-mirtazapine.
10. The process according to claim 5 , wherein the optically active tartaric acid is L-tartaric acid and the obtained optically active mirtazapine is S-mirtazapine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03102095.1 | 2003-07-10 | ||
EP03102095 | 2003-07-10 | ||
PCT/JP2008/061982 WO2009008303A1 (en) | 2007-07-10 | 2008-07-02 | Process for production of optically active mirtazapine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100179319A1 true US20100179319A1 (en) | 2010-07-15 |
Family
ID=34042934
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/564,193 Expired - Fee Related US8058436B2 (en) | 2003-07-10 | 2004-07-05 | Method for the preparation of enantiomerically pure mirtazapine |
US12/667,969 Abandoned US20100179319A1 (en) | 2003-07-10 | 2008-07-02 | Process for production of optically active mirtazapine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/564,193 Expired - Fee Related US8058436B2 (en) | 2003-07-10 | 2004-07-05 | Method for the preparation of enantiomerically pure mirtazapine |
Country Status (36)
Country | Link |
---|---|
US (2) | US8058436B2 (en) |
EP (1) | EP1656365B1 (en) |
JP (1) | JP4668184B2 (en) |
KR (1) | KR20060056315A (en) |
CN (1) | CN100558722C (en) |
AR (1) | AR046494A1 (en) |
AT (1) | ATE433965T1 (en) |
AU (1) | AU2004255874B2 (en) |
BR (1) | BRPI0412447A (en) |
CA (1) | CA2531165C (en) |
CO (1) | CO5640123A2 (en) |
CY (1) | CY1109327T1 (en) |
DE (1) | DE602004021605D1 (en) |
DK (1) | DK1656365T3 (en) |
EC (1) | ECSP066271A (en) |
ES (1) | ES2327123T3 (en) |
HK (1) | HK1086841A1 (en) |
HR (1) | HRP20051019A2 (en) |
IL (1) | IL172549A0 (en) |
IS (1) | IS2674B (en) |
LT (1) | LT5382B (en) |
LV (1) | LV13441B (en) |
MX (1) | MXPA06000325A (en) |
NO (1) | NO20056175L (en) |
NZ (1) | NZ544360A (en) |
PE (1) | PE20050323A1 (en) |
PL (1) | PL1656365T3 (en) |
PT (1) | PT1656365E (en) |
RS (1) | RS20050972A (en) |
RU (1) | RU2352566C2 (en) |
SG (1) | SG144914A1 (en) |
SI (1) | SI1656365T1 (en) |
TW (1) | TWI335915B (en) |
UA (1) | UA83666C2 (en) |
WO (1) | WO2005005410A1 (en) |
ZA (1) | ZA200600019B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102126978A (en) * | 2005-09-26 | 2011-07-20 | 住友化学株式会社 | Process for producing optically active piperazine compound |
JP5080050B2 (en) * | 2005-09-26 | 2012-11-21 | 住友化学株式会社 | Method for producing optically active piperazine compound |
TW200808804A (en) * | 2006-05-22 | 2008-02-16 | Organon Nv | Mirtazapine for the treatment of neuropathic pain |
TW200815370A (en) * | 2006-06-16 | 2008-04-01 | Organon Nv | Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine |
WO2008099715A1 (en) * | 2007-02-09 | 2008-08-21 | Kaneka Corporation | Method for producing optically active 2-arylpiperazine derivative |
JP5192707B2 (en) * | 2007-03-22 | 2013-05-08 | 住友化学株式会社 | Manufacturing method of mirtazapine |
US7994314B2 (en) | 2007-04-11 | 2011-08-09 | N.V. Organon | Method for the preparation of an enantiomerically pure benzazepine |
CN101679431B (en) * | 2007-04-11 | 2013-08-14 | Msd欧斯股份有限公司 | Method for preparation of enantiomer of tetracyclic benzazepine |
KR101485418B1 (en) * | 2013-05-29 | 2015-01-26 | 주식회사 메디켐코리아 | A synthetic method of high purity mirtazapine |
DK3261645T3 (en) | 2015-02-27 | 2021-06-07 | Dechra Ltd | Stimulation of appetite, management of weight loss and treatment of anorexia in dogs and cats |
KR102540021B1 (en) * | 2020-12-02 | 2023-06-07 | (주)유케이케미팜 | Method for preparing mirtazapine suitable for mass production |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
US5461051A (en) * | 1989-10-05 | 1995-10-24 | Sankyo Company, Limited | Tetracyclic compounds having anti-allergic and anti-asthmatic activities and their use |
US20070111993A1 (en) * | 2004-04-21 | 2007-05-17 | Akzo Nobel N.V. | Pharmaceutical composition comprising a salt of mirtazapine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959470A (en) * | 1972-11-28 | 1976-05-25 | Mikhail Davidovich Mashkovsky | Psychotropic medicinal preparation |
JPH11222407A (en) * | 1997-11-14 | 1999-08-17 | Sankyo Co Ltd | New microbicidal |
CN1154495C (en) | 1997-11-14 | 2004-06-23 | 阿克佐诺贝尔公司 | Use of mirtazapine for treating sleep apneas |
SK14672001A3 (en) * | 1999-04-19 | 2002-11-06 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
US20030069417A1 (en) * | 1999-04-19 | 2003-04-10 | Claude Singer | Novel synthesis and crystallization of piperazine ring-containing compounds |
US6068695A (en) * | 1999-07-13 | 2000-05-30 | Bayer Corporation | Process for the continuous preparation of quinacridones |
WO2001025185A1 (en) | 1999-09-30 | 2001-04-12 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a piperazine derivative |
WO2001042239A1 (en) * | 1999-12-13 | 2001-06-14 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a pyridinemethanol compound |
IL150290A0 (en) | 2000-02-11 | 2002-12-01 | Akzo Nobel Nv | The use of mirtazapine for the treatment of sleep disorders |
JP2001342188A (en) * | 2000-03-27 | 2001-12-11 | Takeda Chem Ind Ltd | Condensed pyrazole derivative, and its production method and use |
-
2004
- 2004-05-07 UA UAA200600274A patent/UA83666C2/en unknown
- 2004-06-28 TW TW093118845A patent/TWI335915B/en not_active IP Right Cessation
- 2004-07-05 SI SI200431183T patent/SI1656365T1/en unknown
- 2004-07-05 US US10/564,193 patent/US8058436B2/en not_active Expired - Fee Related
- 2004-07-05 PT PT04741958T patent/PT1656365E/en unknown
- 2004-07-05 CN CNB2004800194891A patent/CN100558722C/en active Active
- 2004-07-05 MX MXPA06000325A patent/MXPA06000325A/en active IP Right Grant
- 2004-07-05 KR KR1020067000511A patent/KR20060056315A/en active IP Right Grant
- 2004-07-05 JP JP2006518216A patent/JP4668184B2/en active Active
- 2004-07-05 EP EP04741958A patent/EP1656365B1/en active Active
- 2004-07-05 CA CA2531165A patent/CA2531165C/en not_active Expired - Fee Related
- 2004-07-05 NZ NZ544360A patent/NZ544360A/en not_active IP Right Cessation
- 2004-07-05 SG SG200805127-8A patent/SG144914A1/en unknown
- 2004-07-05 RU RU2006103992/04A patent/RU2352566C2/en not_active IP Right Cessation
- 2004-07-05 DK DK04741958T patent/DK1656365T3/en active
- 2004-07-05 BR BRPI0412447-2A patent/BRPI0412447A/en not_active IP Right Cessation
- 2004-07-05 ES ES04741958T patent/ES2327123T3/en active Active
- 2004-07-05 WO PCT/EP2004/051357 patent/WO2005005410A1/en active IP Right Grant
- 2004-07-05 PL PL04741958T patent/PL1656365T3/en unknown
- 2004-07-05 AT AT04741958T patent/ATE433965T1/en active
- 2004-07-05 RS YUP-2005/0972A patent/RS20050972A/en unknown
- 2004-07-05 DE DE602004021605T patent/DE602004021605D1/en active Active
- 2004-07-05 AU AU2004255874A patent/AU2004255874B2/en active Active
- 2004-07-07 PE PE2004000653A patent/PE20050323A1/en not_active Application Discontinuation
- 2004-07-08 AR ARP040102412A patent/AR046494A1/en not_active Application Discontinuation
-
2005
- 2005-12-12 LT LT2005107A patent/LT5382B/en not_active IP Right Cessation
- 2005-12-13 IL IL172549A patent/IL172549A0/en not_active IP Right Cessation
- 2005-12-15 IS IS8184A patent/IS2674B/en unknown
- 2005-12-22 HR HR20051019A patent/HRP20051019A2/en not_active Application Discontinuation
- 2005-12-23 NO NO20056175A patent/NO20056175L/en not_active Application Discontinuation
-
2006
- 2006-01-03 ZA ZA200600019A patent/ZA200600019B/en unknown
- 2006-01-09 EC EC2006006271A patent/ECSP066271A/en unknown
- 2006-01-10 CO CO06001617A patent/CO5640123A2/en not_active Application Discontinuation
- 2006-02-10 LV LVP-06-21A patent/LV13441B/en unknown
- 2006-08-17 HK HK06109133.3A patent/HK1086841A1/en not_active IP Right Cessation
-
2008
- 2008-07-02 US US12/667,969 patent/US20100179319A1/en not_active Abandoned
-
2009
- 2009-08-25 CY CY20091100894T patent/CY1109327T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062848A (en) * | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
US5461051A (en) * | 1989-10-05 | 1995-10-24 | Sankyo Company, Limited | Tetracyclic compounds having anti-allergic and anti-asthmatic activities and their use |
US20070111993A1 (en) * | 2004-04-21 | 2007-05-17 | Akzo Nobel N.V. | Pharmaceutical composition comprising a salt of mirtazapine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100179319A1 (en) | Process for production of optically active mirtazapine | |
US11897843B2 (en) | Process for the preparation of enantiomerically enriched 3-aminopiperidine | |
US20030087930A1 (en) | Process for preparing 2-(4-chlorobenzolamino)-3[ (1h)-quinolinon-4-yl] propionic acid | |
JP5387040B2 (en) | Method for optical resolution of alkylpiperidin-3-ylcarbamate and intermediates thereof | |
EP1466905B1 (en) | Process for producing optically active oxoheptenoic acid ester | |
JPH11116570A (en) | Production of dihydropyridine derivative | |
EP0990647B1 (en) | Process for producing quinolone derivatives | |
JP4783998B2 (en) | Preparation of (3R, 5S) -7-substituted-3,5-dihydroxyhept-6-enoic acid | |
EP2174940A1 (en) | Process for production of optically active mirtazapine | |
WO2011010579A1 (en) | Process for production of optically active nipecotamide | |
KR960008243B1 (en) | Hetero cyclic compound | |
ES2383667T3 (en) | Process for producing a quinolinecarboxialdehyde derivative and an intermediate thereof | |
JP4326471B2 (en) | Method for producing organic compound | |
TW201815779A (en) | Production method of (R)-5-(3,4-difluorophenyl)-5-{(3-methyl-2-oxopyridin-1(2H)-yl)methyl}imidazolidine-2,4-dione and intermediate for producing the same | |
JP4300739B2 (en) | Preparation of 2-amino-5-halogenoindole | |
JP2002371060A (en) | Method for producing optically active aminopiperidine derivative | |
JP3529425B2 (en) | Method for producing (S) -3-lower alkyl-2-piperazinone | |
JP4449211B2 (en) | 6- (1-fluoroethyl) -5-iodo-4-pyrimidone and process for producing the same | |
JP5503930B2 (en) | Method for purifying 3-amino-1-tert-butoxycarbonylpiperidine and citrate salt thereof | |
JP2011026201A (en) | Stereo-selective method of producing optically active pyrrolyl-succinimide derivative | |
JP2006137693A (en) | Carboxylate of 2-acyloxy-3-(4-tetrahydropyranyl)-3-amino-2-propenoate and its production method | |
JPH07196612A (en) | 1,4-dihydropyridine derivative and production of 1,4-dihydropyridinecarboxylic acid derivative using the same | |
JP2003055357A (en) | Method for producing 3,4-epoxybutanoic acid ester | |
JP2006315967A (en) | Method for optical resolution of dihydrobenzofuran derivative or chroman derivative | |
JP2013100279A (en) | Method of producing mandelic acid amide derivative and intermediate of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUMITOMO CHEMICAL COMPANY, LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, WEIQI;IKEMOTO, TETSUYA;REEL/FRAME:023954/0595 Effective date: 20091217 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |